Moderna lowers 2025 sales forecast by $1 billion

Modern On Monday, it cut its 2025 sales guidance by about $1 billion because of some potential headwinds later this year as the biotech company continues to cut costs and expand its portfolio.

Moderna now expects 2025 revenue to be between $1.5 billion and $2.5 billion, most of which will come in the second half of the year. Most of these sales come from Moderna’s Covid vaccine and the new vaccine launched for respiratory syncytial virusaccording to a press release.

The guide is lowered from a previous one forecast range of $2.5 billion to $3.5 billion issued in September. At the time, the company said it was waiting break even on an operating cash basis in 2028 — pushed back from 2026 — with $6 billion in revenue.

Moderna’s shares soared 18% in premarket trading on Monday. Other vaccine stocks also fell, with Novavax down 6% ahead of the open market, BioNTech down 3% and Pfizer flat.

“As we go into 2025, there are a handful of uncertainties that we’re planning for,” Moderna CFO Jamey Mock told CNBC. “In this period of time, we plan for them to be headwinds. They could be tailwinds, but now we see them as headwinds.”

Mock pointed to four factors that could weigh on sales, including an increase in competition in the Covid market. He said Moderna’s share of the US retail market as Covid hits has fallen to 40% by the end of 2024 from 48% in 2023, and the company is preparing for a another drop this year.

He noticed Sanofi will co-market NovavaxThe worldwide Covid vaccine under a new agreement, which could potentially make that shot more competitive.

Mock said that the second factor is falling vaccination rates, which were down around 7% overall in the US sales market in the fall of 2024 compared to the same time in 2023. The last two factors are timing around manufacturing contracts with a handful of countries, and uncertainty. around what Centers for Disease Control and Prevention advisors recommend for RSV revaccination.

But Mock noted that the company expects to reduce cost expenses in 2025 by $1 billion, with plans for additional 2026 cost reductions of $500 million.

“We take the right amount of cost to preserve our money,” Mock said. “We are excited to invest and diversify our portfolio.”

The announcement comes as Moderna charts a way forward after the rapid decline in demand for its Covid vaccine, its only commercially available product until its RSV shot entered the market last year. It is also ahead of the presentation of Moderna to the year JPMorgan Healthcare Conferenceone of the largest gatherings of healthcare leaders in the world and a hotbed for bidding activity for the industry.

Revenue from Moderna’s two hits met its forecast for 2024, coming in at around $3 billion to $3.1 billion. In November, the company announced its updated Covid hit benefited to get approval in the United States three weeks before the previous iteration of the shot in 2023.

However, those sales represent a sharp drop from the $6.7 billion that the encounter of Moderna Covid reserved in 2023 and the 18 billion dollars it generated in 2022, since fewer people risked the sleeves for updated jabs.

Moderna plans to bolster its portfolio with 10 new product approvals over the next three years, including a combination shot targeting Covid and flu and a “next-generation” Covid shot. The company on Monday said it could see three approvals in 2025 alone.

The company is betting on a pipeline built around its messenger RNA platform, which is the technology used in its Covid vaccine and RSV vaccine.